The MAD7 nuclease: Made for discovery.

It’s time to get MAD

Not all nucleases are created equal. They vary in size, structure, PAM requirements, and many other characteristics. Selecting the one that best fits your research needs is an important step for successful genome engineering. 
So, what is MAD7? It is a type V CRISPR nuclease isolated from Eubacterium rectale, found on the island of Madagascar. MAD7 recognizes a thymidine-rich PAM sequence (5′-NTTV‑3′) upstream of crRNA and uses a single domain to create sequence specific double strand cuts (with staggered ends) in target DNA.

Benefits

Cas nuclease
Versatile
  • Inscripta scientists and independent researchers have shown MAD7 effectively generates indels in a range of organisms: microbes, plants, mammalian cell lines, iPSCs, and animal models
  • MAD7’s thymidine-rich PAM recognition provides genome scale access for editing in diverse cell systems.
1 0 icon 2 performance
Proven Performance
  • Type V nucleases such as MAD7, in general, have lower off-target effects as compared to type II nucleases
  • A single nuclease domain creates double stranded breaks with staggered overhangs that can aid in HDR mediated experiments
  • Smaller size and payload are optimal for viral and plasmid delivery methods
1 0 icon 2 access
Greater Access
  • Non-exclusive licenses are available for various research, development, and commercial applications
  • Hundreds of scientists in academia and industry have licensed & utilized MAD7 since its release in 2017

Providing additional options for CRISPR-based research

The last thing you should have to worry about in product development is choosing the right CRISPR nuclease. You need licensing access to any field or application you wish to work on.

Inscripta developed and released the MAD7 nuclease to the global research community in 2017 under a broad technology access program to democratize access to CRISPR and promote its widespread adoption in both academic and commercial settings. 

Inscripta will soon offer a portfolio of MADzyme nucleases under an expanded, non-exclusive licensing program, including several MAD7 variants with improved properties such as expanded PAM sites, and higher fidelity. Please contact us below to learn more.

Coming Soon! Wild type MAD7 protein will be available to purchase off-the-shelf from our trusted partners at Aldevron. See the press release.

MAD7 nuclease structural model
Separator

MADzyme licenses

Inscripta believes that CRISPR technology is transformative and can offer technical solutions to many of today’s most challenging biological questions. Based on this philosophy, over the past several years, Inscripta has supported the global research and development community in both academia and industry with the MAD7 nuclease under Inscripta’s technology access program that democratized access to gene editing.
We are committed to providing CRISPR alternatives and will soon offer non-exclusive access to an expanded portfolio of MADzyme nucleases under commercially reasonable terms. For more information on licensing of the MAD7 nuclease or other MADzymes, please contact us.
Separator

The MAD7 nuclease in mammalian cells

In addition to robust performance in prokaryotic and eukaryotic microbial systems, the MAD7 nuclease has demonstrated editing activity in mammalian cells.
For example, initial experiments in HEK293T cells show that the MAD7 nuclease can be expressed as an active protein in mammalian cells, and when combined with synthetic guide RNAs, can edit different genes at multiple loci.
Separator

How well does it work?

If you are wondering how well does the MAD7 nuclease work?”, we have performed extensive characterization and testing of the MAD7 nuclease in both microbial and mammalian systems. Here you can find the technical data on the editing efficiency and performance in yeast and E. coli, the structure of the MAD7 nuclease and preferred PAM sites, expression recommendations, and how to get started using the MAD7 nuclease in your lab.

Separator

The MAD7 nuclease in the news

A key part of Inscripta’s mission is making genome engineering more accessible. Read about the recent publications, novel applications, and other MAD7 nuclease news.